# SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer

> **NCT01542294** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 71 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** s1
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT01542294
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-06
- **Primary completion:** 2014-09
- **Final completion:** 2017-04
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2016-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01542294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01542294, "SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01542294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*